Company Overview

Elk OrthoBiologics is an Australian biotechnology company developing a minimally invasive biologic therapy for repairing aseptically loosened hip and knee prosthetic implants. Aseptic loosening is the most common cause of prosthetic hip failure and a significant cause of prosthetic knee failure.

Elk's lead program, CTL102/CB1954, is a Gene Directed Enzyme Prodrug Therapy (GDEPT), where a short acting therapy removes the soft synovial-like tissue from around a loosened prosthetic implant, allowing the existing prosthesis to be re-cemented to the bone. In recent clinical trial studies, these critical steps have been demonstrated in elderly patients without the need for major surgery and without general anesthesia. As revision surgery is the only current treatment for aseptic loosening, there are many sufferers who have no treatment option because of other health concerns.

Elk’s clinical partner is the Leiden University Medical Center, in Leiden, the Netherlands. Australia’s premier research institution, CSIRO, is a major shareholder.